Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PSAI vs AHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHG Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

AHG Overall Winner 6-Pillar Tally: PSAI 0 – 5 AHG (1 Tie) Matrix Metrics: PSAI 3 – 5 AHG

As of Nov 16, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over PSAI (PSAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PSAI carries a Unified Composite Score of 54.8/100 (HOLD) at $29.30 (N/M Forward P/E, N/A operating margin), whereas AHG carries 42.6/100 (HOLD) at $1.33 (N/M Forward P/E, -28.9% operating margin).

  • Composite vs. Pillar Nuance: While PSAI currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. AHG 42.6/100 HOLD), AHG captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PSAI vs AHG
PSAI US Equity
PSAI
Institutional Equity
$29.30
-0.86% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.80β · 13% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 50.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 57
RSI-14: 56.6 · SMA20: $29.16 · SMA50: $28.39
AHG NASDAQ Head-to-Head Winner
Akso Health Group ADS
Services-Business Services, Nec
$1.33
+7.26% 1D
Market Cap $1.1B
TTM Revenue $14M
Forward P/E N/M
Beta / 30D Vol 0.16β · 97% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.5% over 20 days), RSI 54
RSI-14: 54.2 · SMA20: $1.29 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (PSAI 0 – 5 AHG)

Columns: Metric · PSAI · AHG
1. Valuation Multiples AHG
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 76.8x
2. Growth & Scale AHG
Revenue Growth (YoY) N/A -12.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $14M
Market Cap N/A $1.1B
3. Profitability & Quality AHG
Gross Margin N/A -0.1%
Operating Margin N/A -28.9%
Net Profit Margin N/A -135.0%
Return on Equity (ROE) N/A -9.8%
4. Balance Sheet & Cash Flow AHG
Cash Generation (TTM) N/A -$1.6M EBITDA
Cash Flow Margin N/A -11.8% EBITDA Mgn
Net Cash / Leverage N/A ROE $0.21 Book/Sh · -9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AHG
OpEx & R&D Intensity N/A 28.8% of Rev ($4.0M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PSAI (3) vs AHG (5)
Institutional Metric PSAI AHG Criterion Row Edge
Market Capitalization
Scale
N/A $1.1B Larger Scale AHG
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -12.9% Higher Growth AHG
Operating Margin (TTM)
Profitability
N/A -28.9% Higher Margin AHG
Net Profit Margin
Profitability
N/A -135.0% Higher Margin AHG
Return on Equity (ROE)
Capital Efficiency
N/A -9.8% Higher ROE AHG
52-Week Range Position
Momentum
91% ($25–$30) 36% ($1–$2) Stronger Trend PSAI
Beta / 30D Volatility
Risk Regime
0.80β · 13% Vol 0.16β · 97% Vol Lower Realized Risk PSAI
Unified Institutional Score
Composite Signal
54.8 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite PSAI
Trailing 12M Revenue (USD)
Operating Scale
N/A $14M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -0.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 76.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$1.6M EBITDA ($0.21 Book/Sh · -9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSAI +3.39 pp
PSAI: +1.91% · AHG: -1.48%
3M Horizon AHG +24.46 pp
PSAI: +2.81% · AHG: +27.27%
6M Horizon PSAI +37.13 pp
PSAI: +14.01% · AHG: -23.12%
1Y Horizon PSAI +49.41 pp
PSAI: +14.29% · AHG: -35.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PSAI vs AHG. Trailing 12-month operating profitability (PSAI N/A vs AHG -28.9%) and valuation multiples (PSAI N/M vs AHG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PSAI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14M
Gross Margin-0.1%
Op. Margin-28.9%
ROE / Fwd P/E-9.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PSAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PSAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PSAI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $1.1B market capitalization and -28.9% operating margin.
OpEx & R&D Reinvestment 28.8% of Rev ($4.0M)
90D Engineering Disclosures 0 Published

Investor FAQ PSAI vs AHG Key Questions & Quantitative Answers

As of Nov 16, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over PSAI (PSAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PSAI carries a Unified Composite Score of 54.8/100 (HOLD) at $29.30 (N/M Forward P/E, N/A operating margin), whereas AHG carries 42.6/100 (HOLD) at $1.33 (N/M Forward P/E, -28.9% operating margin). Composite vs. Pillar Nuance: While PSAI currently prints a higher short-term Unified Composite Score (54.8/100 HOLD vs. AHG 42.6/100 HOLD), AHG captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY).

AHG leads the Growth & Scale pillar: PSAI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AHG at -12.9% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (-0.1% gross margin, -28.9% operating margin). On trailing 12-month operating scale, PSAI generates N/A in USD-normalized revenue versus $14M for AHG. In operating R&D and SG&A reinvestment, PSAI deploys N/A (0 90-day corporate R&D disclosures) versus 28.8% of Rev ($4.0M) (0 disclosures) for AHG.

AHG screens cheaper on headline valuation multiples. PSAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AHG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 76.8x EV/Revenue (-11.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PSAI (N/A ROE) versus AHG (-9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, PSAI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 13% Vol realized risk). By comparison, AHG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.16β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.